Last reviewed · How we verify
Pioglitazone or metformin
At a glance
| Generic name | Pioglitazone or metformin |
|---|---|
| Sponsor | Beth Israel Deaconess Medical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy (PHASE4)
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. (PHASE4)
- A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (PHASE4)
- Prevention of Progression of Prediabetes, Obesity and CV Risk (PHASE1)
- Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) (NA)
- HbA1c Variability in Type II Diabetes (NA)
- Changing the Natural History of Type 2 Diabetes ("CHANGE" Study) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pioglitazone or metformin CI brief — competitive landscape report
- Pioglitazone or metformin updates RSS · CI watch RSS
- Beth Israel Deaconess Medical Center portfolio CI